Inactive Instrument

Integrity Applications, Inc. Stock Other OTC

Equities

IGAP

US45824Q1013

Biotechnology & Medical Research

Sales 2022 - Sales 2023 - Capitalization 5.46M
Net income 2022 -4M Net income 2023 -7M EV / Sales 2022 -
Net cash position 2022 2.12M Net cash position 2023 4.3M EV / Sales 2023 -
P/E ratio 2022
-4.92 x
P/E ratio 2023
-0.68 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 65.25%
More Fundamentals * Assessed data
Dynamic Chart
Glucotrack Expanding Glucose Monitoring Technology to Epidural Space MT
GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring CI
Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor CI
GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors CI
GlucoTrack Says Implantable Glucose Monitor Safe With High Level of Accuracy; Shares Rise MT
GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor CI
GlucoTrack, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GlucoTrack Finance Chief Jolie Kahn Resigns, James Cardwell Named New CFO MT
GlucoTrack, Inc. Announces Executive Changes CI
Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee CI
GlucoTrack, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor CI
Certain Common Stock of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 13-JUN-2023. CI
GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
Managers TitleAgeSince
Chief Executive Officer 56 20-12-16
Director of Finance/CFO 64 23-10-10
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 57 19-07-07
Chairman 61 Feb. 12
Director/Board Member 95 09-12-31
More insiders
GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an approximately two-year implant longevity without the requirement for any wearable components. The CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time. The Company is also developing the Glucotrack CBGM a companion mobile application and a cloud-based solution to provide real time, data-driven personalized tools to effectively help a user manage their diabetes and assist healthcare providers with making treatment decisions.
More about the company